
Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus, known for its roles in social attachment, trust, empathy, and anxiety regulation. It has been investigated in hundreds of clinical studies for social cognition, anxiety, autism spectrum disorder, and PTSD.
Intranasal oxytocin is investigational for most indications. Results are promising but nuanced — context and individual differences matter significantly. This is not medical advice.
Quick Reference: Standard Protocol
| Parameter |
Detail |
| Vial |
10 mg |
| BAC Water |
10 mL |
| Concentration |
1 mg/mL (1,000 mcg/mL) |
| Dose |
50 mcg (5 units on insulin syringe) |
| Route |
Subcutaneous |
| Timing |
AM |
| Frequency |
As needed |
| Cycle |
As needed |
| Storage |
Refrigerate, use within 28 days |
Intranasal alternative: 24 IU (3 puffs per nostril at 4 IU per puff), 30-45 minutes before desired effect.
For the full oxytocin peptide profile and vendor pricing, see our oxytocin peptide page.
Cycling Details
Oxytocin is dosed as needed — no traditional loading or cycling. Effects are acute and do not build over time the way other peptides do.
Acute dosing (most research): A single dose administered 30-45 minutes before a social task or assessment. This is the protocol used in the majority of published studies.
Chronic dosing (clinical trials): Multi-week protocols in autism and PTSD trials typically use 24 IU twice daily for 4-12 weeks. Receptor desensitization is a theoretical concern with daily use, so some users cycle 4 weeks on / 2 weeks off as a precaution.
Routes of Administration
Intranasal spray is the primary research route, believed to provide direct nose-to-brain transport via the olfactory and trigeminal nerve pathways. Standard protocol: 3 puffs per nostril (24 IU total at 4 IU per puff), wait 30 seconds between puffs. Effects begin in 30-45 minutes.

Subcutaneous injection targets peripheral OT receptors on sensory neurons. Very little crosses the blood-brain barrier from SubQ, so effects are primarily pain modulation and anti-inflammatory activity. A trial showed just 4 mcg SubQ significantly reduced heat pain intensity (Rash et al., 2024).
Key distinction: Intranasal = CNS effects (anxiety, trust, social cognition). Subcutaneous = peripheral effects (pain, inflammation). Choose route based on target.
Reconstitution Quick Reference
| Vial Size |
BAC Water |
Concentration |
50 mcg Dose |
| 10 mg |
10 mL |
1 mg/mL |
5 units |
Math: 10 mg / 10 mL = 1 mg/mL = 1,000 mcg/mL. For 50 mcg: 50 / 1,000 = 0.05 mL = 5 units.
Swirl gently — do not shake. Refrigerate at 2-8 C, use within 28 days. For intranasal use, vials are typically compounded into nasal sprays by pharmacies.
Where These Numbers Come From
Oxytocin research spans hundreds of studies, though effect sizes and reproducibility are subjects of ongoing scientific debate.
Trust and prosocial behavior: The landmark Kosfeld et al. study demonstrated that 24 IU intranasal oxytocin increased trust behavior in a trust game paradigm (Kosfeld et al., 2005). Subsequent replications show smaller effect sizes but generally support context-dependent prosocial effects.
Social anxiety: Intranasal oxytocin (24 IU) enhanced the efficacy of exposure therapy for social anxiety disorder, suggesting utility as an adjunct to psychotherapy (Guastella et al., 2009).
Autism spectrum disorder: Results have been mixed. A large RCT in young children (24 IU for 5 months) did not show significant improvements over placebo on primary outcomes (Sikich et al., 2021).
Peripheral pain modulation: Subcutaneous oxytocin at just 4 mcg significantly reduced heat pain intensity via peripheral OT receptors on sensory neurons (Rash et al., 2024).
Stacking Protocols
| Stack |
Purpose |
Protocol |
| Oxytocin + Psychotherapy |
Strongest evidence — enhanced social learning |
24 IU intranasal 30-45 min before session |
| Oxytocin + DSIP |
Stress/sleep regulation |
OT AM + DSIP PM |
| Oxytocin + PT-141 |
Intimacy (bonding + arousal) |
OT 50 mcg + PT-141 500 mcg, 30 min before |
Start oxytocin alone to assess individual response before combining. Context matters enormously — oxytocin effects are highly dependent on social environment.
Side Effects & Safety
- Nasal irritation — mild, usually transient (intranasal route)
- Headache — occasional, typically mild
- Drowsiness — reported in some individuals
- Context-dependent emotional effects — may amplify negative emotions in unsupportive social contexts
- Uterotonic effects — contraindicated in pregnancy (stimulates uterine contractions)
- Receptor desensitization — theoretical concern with chronic daily use
- No serious adverse events reported in published clinical trials
Frequently Asked Questions
What is the standard oxytocin dose?
For subcutaneous injection, 50 mcg in the morning as needed (10 mg vial with 10 mL BAC water = 5 units). For intranasal, 24 IU (3 puffs per nostril) 30-45 minutes before desired effect.
How long does intranasal oxytocin take to work?
Effects begin within 30-45 minutes, corresponding to peak CSF concentrations. Effects typically last 2-4 hours.
Is oxytocin nasal spray safe?
Acute single-dose use has an excellent safety profile across hundreds of studies. Long-term daily use (>12 weeks) has limited safety data. Side effects are generally mild.
Can oxytocin help with social anxiety?
Evidence suggests it can reduce amygdala reactivity to social threats and enhance exposure therapy effectiveness. It likely works best as an adjunct to therapy rather than standalone treatment.
Is oxytocin the same as Pitocin?
Same molecule, different route and indication. Pitocin is IV oxytocin for labor induction. Intranasal oxytocin targets brain delivery for social/cognitive effects at much lower systemic doses.
Can oxytocin be used daily long-term?
Most clinical trials run 4-12 weeks with twice-daily dosing. Receptor desensitization is a theoretical concern. Some users cycle 4 weeks on / 2 weeks off as a precaution.
References
| Citation |
Topic |
PMID |
| Kosfeld et al., Nature (2005) |
Intranasal oxytocin increases trust in humans |
15931222 |
| Guastella et al., Biological Psychiatry (2009) |
Oxytocin as adjunct to exposure therapy |
19246160 |
| Guastella et al., Psychoneuroendocrinology (2013) |
Standardization of intranasal oxytocin administration |
23265311 |
| Sikich et al., New England Journal of Medicine (2021) |
Oxytocin RCT in young children with autism |
36302965 |
| Rash et al., Pain (2024) |
Subcutaneous oxytocin reduces heat pain intensity |
38642595 |
| Churchland & Winkielman, Hormones and Behavior (2012) |
Critical review of intranasal oxytocin effects |
24239931 |
For educational and research purposes only. This is not medical advice. Intranasal oxytocin is investigational for most indications discussed.